当前位置:首页 - 行情中心 - 佰仁医疗(688198) - 财务分析 - 利润表

佰仁医疗

(688198)

  

流通市值:140.51亿  总市值:140.51亿
流通股本:1.37亿   总股本:1.37亿

利润表

报告期2025-03-312024-12-312024-09-302024-06-30
公司类型通用通用通用通用
一、营业总收入100,139,512.37501,879,121.74292,324,016.69190,683,312.95
营业收入100,139,512.37501,879,121.74292,324,016.69190,683,312.95
二、营业总成本80,035,115.12362,250,854.74245,184,032.93163,454,440.27
营业成本14,300,970.4858,524,711.4433,427,904.0620,456,064.06
税金及附加1,344,071.214,198,830.332,384,147.131,761,879.82
销售费用23,410,959.55121,961,231.7681,737,233.2653,610,777.11
管理费用8,399,826.5232,960,162.4222,407,154.0614,903,144.64
研发费用33,115,530.01151,441,921.38108,992,107.8677,066,518.91
财务费用-536,242.65-6,836,002.59-3,764,513.44-4,343,944.27
其中:利息费用106,564.61462,630.48358,594.35241,840.89
其中:利息收入731,930.227,309,673.954,789,476.854,681,567.75
加:公允价值变动收益497,473.03742,302.66643,981.26313,887.64
加:投资收益1,981,442.3910,011,207.197,632,128.65,553,541.83
资产处置收益-362.99149.61-
信用减值损失(新)67,144.98-2,488,383.41-612,526.8-283,060.28
其他收益14,490,211.755,326,472.294,366,528.652,387,716.13
营业利润平衡项目0000
四、营业利润37,140,669.4153,220,228.7259,170,245.0835,200,958
加:营业外收入34,634.1447,054.0146,436.4644,332.35
减:营业外支出2,500,0002,481,067.582,170,714.35631,069.86
利润总额平衡项目0000
五、利润总额34,675,303.54150,786,215.1557,045,967.1934,614,220.49
减:所得税费用4,493,024.8918,642,719.467,040,113.526,564,468.78
六、净利润30,182,278.65132,143,495.6950,005,853.6728,049,751.71
持续经营净利润30,182,278.65132,143,495.6950,005,853.6728,049,751.71
归属于母公司股东的净利润32,504,318.17146,330,147.7158,693,362.2335,190,693.59
少数股东损益-2,322,039.52-14,186,652.02-8,687,508.56-7,140,941.88
(一)基本每股收益0.241.070.430.26
(二)稀释每股收益0.241.070.430.26
八、其他综合收益-32,950.47320,537.92-296,622.83262,581.93
归属于母公司股东的其他综合收益-32,950.47320,537.92-296,622.83262,581.93
九、综合收益总额30,149,328.18132,464,033.6149,709,230.8428,312,333.64
归属于母公司股东的综合收益总额32,471,367.7146,650,685.6358,396,739.435,453,275.52
归属于少数股东的综合收益总额-2,322,039.52-14,186,652.02-8,687,508.56-7,140,941.88
公告日期2025-04-252025-04-252024-10-302024-08-22
审计意见(境内)标准无保留意见
TOP↑